Goserelin ('Zoladex')-offering patients more choice in early breast cancer.
AffiliationChristie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractThe luteinising hormone-releasing hormone analogue goserelin ('Zoladex') suppresses ovarian oestrogen production in pre- and perimenopausal women. Goserelin is a biodegradable, sustained-release 3.6 mg depot that is administered by subcutaneous injection every 28 days. Clinical trials in premenopausal women with hormone-sensitive early breast cancer have demonstrated that goserelin alone, or in combination with tamoxifen, is at least as effective as cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy. Goserelin plus tamoxifen after cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) chemotherapy resulted in improved disease-free survival compared with CAF alone. These trials have also shown that goserelin is well tolerated and is associated with less acute toxicity than cytotoxic chemotherapy. Early improvements in quality of life over the first 3-6 months of goserelin treatment support the use of this agent as an alternative to chemotherapy in this patient population. Patients should be provided with information on the benefits and risks associated with available treatment options so that they can be involved in the decision-making process.
CitationGoserelin ('Zoladex')-offering patients more choice in early breast cancer. 2004, 8 Suppl 2:S95-103 Eur J Oncol Nurs
JournalEuropean Journal of Oncology Nursing
- Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
- Authors: International Breast Cancer Study Group (IBCSG)., Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD
- Issue date: 2003 Dec 17
- The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
- Authors: Robertson JF, Blamey RW
- Issue date: 2003 May
- LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
- Authors: Goel S, Sharma R, Hamilton A, Beith J
- Issue date: 2009 Oct 7
- Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.
- Authors: Kaufmann M
- Issue date: 1998 Sep
- Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
- Authors: Jonat W
- Issue date: 1998 Sep